Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 197

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 197
---
 approvals and achieve product
sales. In addition, our Alpha DaRT technology and other potential future product candidates, if further approved, may not achieve commercial
success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for
many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate
additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever,
as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings,
collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that
we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the
terms of these securities may include liquidation or other preferences that could adversely affect your rights as a shareholder. Any debt
financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such
as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our
business.

If we raise funds through
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate
our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves.

Contractual Obligations and Commitments

The following table summarizes
our significant and non-cancellable contractual obligations as of payment due date by period at December 31, 2024:

                                                        Payments Due by Period Ended December 31,                                                   
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                        Total                                                                                       
  Operating leases (facilities and motor vehicles)      $9,528                                         1,043      905      885      891      5,804  
  Total                                                 $9,528                                         1,043      905      885      891      5,804